MAIA's Phase 2 data at ESMO in September

[cheng_ho]

This will finally tell us whether the second generation of anti-telomerase-positive cell oncology drugs works.

If MAIA's 6-thio-dG works, it will be applicable as an adjunct therapy on the 85% of cancers that are telomerase-positive. A big deal for a $71 million market cap company, and for cancer patients.